Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | DGAT1 | O75907 | 13/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5471114 | 0.85 | DGAT1 (0.57) | NPC1RAB9AHTTSMN1; SMN2POLB | |
| SCHEMBL5459843 | 0.84 | RAB9A (0.55) | NPC1RAB9ASMN1; SMN2MEN1MAPT | |
| SCHEMBL5466937 | 0.83 | KMT2A (0.60) | NPC1RAB9ASMN1; SMN2POLBMEN1 | |
| SCHEMBL5465662 | 0.82 | NPC1 (0.59) | NPC1RAB9AHTTSMN1; SMN2POLB | |
| SCHEMBL5470922 | 0.82 | DGAT1 (0.61) | NPC1RAB9AHTTSMN1; SMN2POLB | |
| SCHEMBL5473462 | 0.79 | DGAT1 (0.53) | DGAT1 | |
| SCHEMBL3544313 | 0.79 | DGAT1 (0.82) | DGAT1 | |
| SCHEMBL5467434 | 0.79 | GAA (0.55) | NPC1RAB9AHTTSMN1; SMN2POLB | |
| SCHEMBL5467414 | 0.79 | CLK2 (0.51) | HTTHDAC3HDAC2MEN1MAPT | |
| SCHEMBL5473556 | 0.79 | DGAT1 (0.57) | NPC1RAB9ADGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249620-A1 | Urea Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1764360-A1 | UREA DERIVATIVE | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249620-A1 | Urea Derivative | UGP2, SLC14A1, DGAT1 | NPC1 1089/4885RAB9A 1528/4885HTT 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.